Immunomedics Appoints Dr. Sol J. Barer Special Advisor to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immunomedics Appoints Dr. Sol J. Barer Special Advisor to the Chairman

MORRIS PLAINS, N.J., April 22, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq: IMMU ) today announced that Dr. Sol J. Barer has been appointed Special Advisor to the Chairman, and will work in this capacity to strengthen the Company’s business and commercial development activities.

Dr. Barer is Managing Partner of SJ Barer Consulting. From 1987 to 2011, he served in various senior management roles at Celgene Corporation, including Executive Chairman, Chairman and CEO, and President and COO. Prior thereto, he was a founder of the biotechnology group at Celanese Corporation, which then became Celgene.

Dr. Barer serves on the Board of Directors of Teva Pharmaceutical Industries, Contrafect, Amicus Therapeutics, and Aegerion Pharmaceuticals, in addition to four other healthcare companies. He received a Ph.D. in organic and physical chemistry from Rutgers University, and a B.S. in chemistry from Brooklyn College of the City of New York.

Dr. David M. Goldenberg, Chairman and Founder of Immunomedics, commented: “The Board of Directors and I are delighted and honored to have such a successful and seasoned biopharmaceutical executive join our team. This is a pivotal time for the Company as we advance our lead antibody-drug conjugate, sacituzumab govitecan, in partnering efforts towards eventual commercialization in the therapy of patients with triple-negative breast cancer as well as other major cancer types.” “We look forward to Dr. Barer playing an important role in the Company’s developments,” Dr. Goldenberg added.

Dr. Barer remarked: “I have observed Immunomedics for many years, since Celgene and Immunomedics both were neighbors in Warren, NJ. I admire the diverse and innovative scientific platforms being developed, and look forward to assisting in strategic development and commercialization of their novel antibody-drug conjugates, as well as immuno-oncology products in early development.” “It is critical to bring these and other compounds in development to the benefit of cancer patients as soon as possible,” Dr. Barer commented further.

About Immunomedics Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of eight clinical-stage product candidates. Immunomedics’ portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxic effects that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics’ most advanced ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase 2 trials for a number of solid tumors and metastatic colorectal cancer, respectively. IMMU-132 has received Breakthrough Therapy Designation from FDA for the treatment of patients with triple-negative breast cancer who have failed at least 2 prior therapies for metastatic disease. Immunomedics has a research collaboration with Bayer to study epratuzumab as a thorium-227-labeled antibody. Immunomedics has other ongoing collaborations in oncology with independent cancer study groups. The IntreALL Inter-European study group is conducting a large, randomized Phase 3 trial combining epratuzumab with chemotherapy in children with relapsed acute lymphoblastic leukemia at clinical sites in Australia, Europe, and Israel. Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and preclinical development. These include combination therapies involving its antibody-drug conjugates, bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its patented DOCK-AND-LOCK ® protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 287 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. For additional information on the Company, please visit its website at www.immunomedics.com . The information on its website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, outcomes, timing or associated costs), out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, new product development (including clinical trials outcome and regulatory requirements/actions), the Company’s dependence on business collaborations in order to further develop our products and finance our operations, the risk that we or any of our collaborators may be unable to secure regulatory approval of and market our drug candidates, risks associated with the outcome of pending litigation and competitive risks to marketed products, and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

For More Information: Dr. Chau Cheng Senior Director, Investor Relations & Corporate Secretary (973) 605-8200, extension 123 ccheng@immunomedics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TNBC Advocate Campaign Targets Gaps in Patient Clarity

Updated Category News Views 103

Triple-negative is a heavy phrase to hand somebody without a map. Tigerlily Foundation and the Breast Cancer Resource Center are trying to close that gap with a national education campaign scheduled to launch publicly on January 11, 2027. The plan is straightforward on paper: train and mobilize 100 patient advocates across the country to explain triple-negative breast...

Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 113

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 20

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
PBS Holiday Special Bets on Apollo 8, Music and Unity

Updated Category News Views 82

A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 16

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 51

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading
Bill Targets 15% Federal Goal for Women-Owned Firms

Updated Category News Views 56

Federal procurement has a stubborn habit of sounding abstract until you remember that contracts can decide whether a small company hires, invests, or simply keeps the lights on. Senator Adam Schiff introduced the Women's Economic Fairness and Small Business Contracting Act on November 19, 2026, proposing to raise the federal goal for Women-Owned Small Businesses from 5%...

Continue Reading
Green Lumber Recall Raises a Serious Safety Question

Updated Category News Views 46

A blister-pack code is doing far more work than it ever should. Green Lumber Holdings is recalling Green Lumber Natural Fuel For Men, lot GL01 with expiration 09/27, after FDA laboratory analysis confirmed undeclared tadalafil in additional samples. The company says the consumer-level recall begins November 19, 2026. This is not a cute labeling nitpick or a marketing...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 63

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 91

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading

Top 5 Most Recently Viewed Articles

InfoSync Services Partners with CogentHub for Strategic Growth

Updated Category News Views 732

InfoSync Services Partners with CogentHub for Strategic Growth In a significant move for the professional services landscape, InfoSync Services, a renowned provider of outsourced solutions, has been sold from Staple Street Capital to CogentHub. This transition marks an exciting chapter not only for InfoSync but also for its clients and the wider market. Understanding...

Continue Reading
Call for Major Economic Stimulus in China: $1.4 Trillion Boost

Updated Category News Views 211

China's Proposal for Economic Stimulus Amid global economic strains, a well-regarded former central bank adviser has put forth a notable idea: China could consider issuing ultra-long-term treasury bonds, which might generate an impressive 10 trillion yuan (around $1.4 trillion) in stimulus. This proactive suggestion was shared at the China Macroeconomy Forum and...

Continue Reading
Cavitation Technologies: Strategic Growth Plans Ahead of 2025

Updated Category News Views 261

Strategic Growth Plans for Cavitation Technologies, Inc. Cavitation Technologies, Inc. (OTCQB: CVAT) is committed to advancing its innovative capabilities in the fields of water treatment and beverage technology. As the company looks toward the future, it aims to capitalize on existing technologies while exploring new partnerships that will enhance its operations....

Continue Reading
How a $1000 Investment in Insulet Transformed Over 15 Years

Updated Category News Views 141

How Insulet Has Thrived Over the Years Insulet (NASDAQ:PODD) has shown remarkable performance, exceeding market expectations over a 15-year span with an impressive annualized return of 23.78%. This is a testament to strong financial growth, significantly outperforming many competitors. The Incredible Growth of a $1000 Investment Consider this: imagine if you invested...

Continue Reading
Synovus Executives Set to Discuss Insights at Conference

Updated Category News Views 70

Synovus Financial Corp. at the BancAnalysts Association Conference Synovus Financial Corp. (NYSE: SNV) is preparing for its participation in a highly anticipated conference that gathers financial experts and analysts. The event will feature a fireside chat with the company’s leadership, including Chairman, CEO, and President Kevin Blair along with Executive Vice...

Continue Reading